Increased Response and Remission Rates in Short-Duration Crohn's Disease With Subcutaneous Certolizumab Pegol: An Analysis of PRECiSE 2 Randomized Maintenance Trial Data

Stefan Schreiber(Christian-Albrechts-Universität zu Kiel), William J. Sandborn(University of San Diego), Jean‐Frédéric Colombel(Mount Sinai Hospital), Ralph Bloomfield(AstraZeneca (United Kingdom)), Jürgen Schölmerich(University of Hohenheim), Susanna Nikolaus(Christian-Albrechts-Universität zu Kiel), Julián Panés(Hospital Clínic de Barcelona)
The American Journal of Gastroenterology
March 16, 2010
10.1038/ajg.2010.78
Cited by 231

Related Papers

Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
|New England Journal of Medicine|2018|2.9k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k